269 related articles for article (PubMed ID: 33538152)
1. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
[TBL] [Abstract][Full Text] [Related]
2. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P
Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925
[TBL] [Abstract][Full Text] [Related]
3. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP; Olszewski AJ; Evens AM; Collins GP; Danilov AV; Bower M; Jagadeesh D; Zhu C; Sperling A; Kim SH; Vaca R; Wei C; Sundaram S; Reddy N; Dalla Pria A; D'Angelo C; Farooq U; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Kassam S; Yazdy M; Rabinovich E; Post FA; Varma G; Karmali R; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein A; Blum KA; Boughan KM; Mian A; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Maliske SM; Epperla N; Caimi P; Smith SE; Kamdar M; Venugopal P; Feldman TA; Rector D; Smith SD; Stadnik A; Portell CA; Lin Y; Naik S; Montoto S; Lossos IS; Cwynarski K
Blood Adv; 2021 Jul; 5(14):2852-2862. PubMed ID: 34283175
[TBL] [Abstract][Full Text] [Related]
4. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
5. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
6. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
[TBL] [Abstract][Full Text] [Related]
7. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
8. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
11. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.
Samra B; Khoury JD; Morita K; Ravandi F; Richard-Carpentier G; Short NJ; El Hussein S; Thompson P; Jain N; Kantarjian H; Jabbour E
Blood Adv; 2021 Oct; 5(20):3913-3918. PubMed ID: 34464974
[TBL] [Abstract][Full Text] [Related]
13. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
[TBL] [Abstract][Full Text] [Related]
14. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era.
Vassilakopoulos TP; Panitsas F; Mellios Z; Apostolidis J; Michael M; Gurion R; Ferhanoglu B; Hatzimichael E; Karakatsanis S; Dimou M; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Giatra H; Kanellias N; Sayyed A; Tadmor T; Akay OM; Angelopoulou MK; Horowitz N; Bakiri M; Pangalis GA; Panayiotidis P; Papageorgiou SG
Hematol Oncol; 2023 Feb; 41(1):97-107. PubMed ID: 36314897
[TBL] [Abstract][Full Text] [Related]
17. Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
Tan JY; Qiu TY; Chiang J; Tan YH; Yang VS; Chang EWY; Poon E; Somasundaram N; Farid M; Tao M; Lim ST; Chan JY
Leuk Lymphoma; 2023 Mar; 64(3):586-596. PubMed ID: 35188049
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
Chin Med J (Engl); 2021 Mar; 134(11):1329-1334. PubMed ID: 33734131
[TBL] [Abstract][Full Text] [Related]
19. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
[TBL] [Abstract][Full Text] [Related]
20. Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.
Baleydier F; Pondarre C; Pages MP; Mialou V; Kebaili K; Pracros JP; Bertrand Y
J Pediatr Hematol Oncol; 2008 Dec; 30(12):972-5. PubMed ID: 19131795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
